ACRS today
$4.14-$0.20 (-4.49%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourLeaning Bearish
15 minSymmetric Triangle
5 minStrong Bearish
Daily trend turns up above $5.76
Key levels
Resistance$4.97
Resistance$4.55
Support$4.08
Support$3.45
Latest news & SEC filings
EarningsAclaris Therapeutics Posts Q3 2026 Results, Gives Clinical Update
EarningsAclaris Therapeutics posts smaller quarterly loss than expected, revenue tops forecast
SEC FilingAclaris Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All ACRS news →About Aclaris Therapeutics
Aclaris Therapeutics is a clinical-stage biopharmaceutical company that develops drug candidates for immune and inflammatory diseases. Its pipeline includes two antibody candidates in-licensed from Biosion, along with earlier-stage programs. The company does not manufacture products itself; it relies on contract manufacturers and contract research organizations, including partners in China, to conduct trials and supply drugs. It intends to collaborate with larger drugmakers and biotech firms to advance and commercialize its candidates.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
Aclaris Therapeutics, Inc. (ACRS)
What Is the Price Target for ACRS?
SEPT Low Target
$8.00
SEPT Mid Target
$10.50
SEPT High Target
$13.00
Analyst Consensus
$10.50
Is ACRS a Buy or Sell Right Now?
Thesis
- •Revenue growing -58.2% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ACRS.
Start Free Trial →Is ACRS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$8.45
7
Moat Score
NONE
2/9
Piotroski Score
-4.7
Altman Z-Score
What Is Smart Money Doing with ACRS?
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ACRS Growth Story
Revenue YoY
-58.2%
3yr Revenue CAGR
-35.9%
EPS Growth YoY
69.01%
FCF Growth YoY
-133.8%
Revenue Trend
DECLINING
Dark Pool Trades for ACRS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ACRS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:52:06 | $4.14 | 1,000 | $$4K | SELL |
| 17:48:25 | $4.14 | 5,000 | $$21K | BUY |
| 17:48:24 | $4.13 | 1,000 | $$4K | SELL |
| 17:40:44 | $4.13 | 1,000 | $$4K | SELL |
| 17:33:22 | $4.14 | 5,032 | $$21K | BUY |
5 dark pool trades shown · $$54K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Aclaris Therapeutics, Inc. (ACRS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ACRS — frequently asked questions
What is ACRS stock price today?
Aclaris Therapeutics, Inc. (ACRS) is at $4.14, down 4.49% (-$0.20) at the Nov 12, 2026 close.
Why is ACRS stock moving today?
Latest ACRS news — Nov 5, 2026: Aclaris Therapeutics Posts Q3 2026 Results, Gives Clinical Update · Nov 5, 2026: Aclaris Therapeutics posts smaller quarterly loss than expected, revenue tops forecast
Why did ACRS stock move on Oct 27, 2026?
Aclaris Therapeutics (ACRS) reported early data supporting its dual-target drug for eczema and asthma, which the company said validates its treatment strategy. However, the stock closed down 4.77% at $3.79 after the company set terms for a $50 million stock sale, a dilutive move that likely pressured shares.
What is the ACRS price target?
The average analyst price target for ACRS is $10.50, ranging from $8 to $13, based on 6 analysts. Latest: Canaccord Genuity maintains on Oct 30, 2026.
What do analysts rate ACRS?
Analyst ratings for ACRS: 0 Buy, 10 Hold, 0 Sell — consensus Hold.
Did ACRS beat earnings?
ACRS last reported on Aug 6, 2026: EPS -$0.15 vs -$0.16 expected — a beat of 6.3%.
Does ACRS pay a dividend?
ACRS does not currently pay a dividend.
What are ACRS support and resistance levels?
Support: $4.08, $3.45, $3.09. Resistance: $4.55, $4.97, $5.76.
What are insiders doing with ACRS?
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
What is the latest news on ACRS?
Nov 5, 2026: Aclaris Therapeutics Posts Q3 2026 Results, Gives Clinical Update · Nov 5, 2026: Aclaris Therapeutics posts smaller quarterly loss than expected, revenue tops forecast · Nov 5, 2026: Aclaris Therapeutics, Inc. filed a report on a major company event (Form 8-K)